Treace Medical Concepts Inc (TMCI)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $345.50M
Last updated: Nov 17, 2026 at 4:10 PM ET
Treace Medical Concepts Inc (TMCI) Statistics
Treace Medical Concepts (TMCI) has a market cap of $345.50M and an enterprise value of $394.00M. It kept -27.44% of revenue as net income over the last 12 months. Its share count is up 3.07% from a year earlier.
Total Valuation
Enterprise value is 14.04% above the market cap, as debt exceeds cash.
| Market Cap | $345.50M |
|---|---|
| Enterprise Value | $394.00M |
| Latest price (Nov 17, 2026) | $4.44 |
Key Dates
The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.4x and 4.7x. Its year-end P/S ranged from 0.7x to 9.6x from 2021 to 2025.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 1.7x |
| P/B Ratio | 4.7x |
| P/TBV Ratio | 6.9x |
Price Statistics
The stock is up 46.53% over 52 weeks and trades 0.45% above its 50-day average.
| Beta (1Y) | 2.16 |
|---|---|
| 52-Week Change | +46.53% |
| 1-Month Change | +14.43% |
| 3-Month Change | -2.63% |
| 6-Month Change | +63.24% |
| 5-Year Change | -80.79% |
| Total Return (1Y) | +46.53% |
| Total Return (3Y CAGR) | -19.27% |
| Total Return (5Y CAGR) | -25.40% |
| Return vs SPY (1Y) | +47.58% |
| Max Drawdown (1Y) | -61.17% |
| Max Drawdown (3Y) | -92.43% |
| Sharpe Ratio (1Y) | 0.55 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $4.42 |
| 200-Day Average | $3.36 |
| 52-Week Range | $1.17 to $5.44 |
| RSI (14 Days) | 48.3 |
| Average Volume (20 Days) | 348.67K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.58x current liabilities, and total debt is 0.91x shareholder equity.
| Current Ratio | 2.58x |
|---|---|
| Quick Ratio | 1.66x |
| Debt / Equity | 0.91x |
| Interest Coverage | -5.56x |
Returns and Efficiency
Return on invested capital is -32.79% over the last 12 months, against a 5-year average of -29.94%.
| Return on Equity (ROE) | -90.51% |
|---|---|
| Return on Assets (ROA) | -31.12% |
| Return on Invested Capital (ROIC) | -32.79% |
| Return on Capital Employed (ROCE) | -36.74% |
| ROE (5Y Average) | -49.13% |
| ROA (5Y Average) | -23.56% |
| ROIC (5Y Average) | -29.94% |
| Asset Turnover | 1.08x |
| Inventory Turnover | 1.02x |
| Receivables Turnover | 6.90x |
| Cash Conversion Cycle | 279 days |
Scores
TMCI has an Altman Z-Score of -0.10, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.10 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $203.35M over the last 12 months is down 7.10% from the 12 months before.
| Revenue | $203.35M |
|---|---|
| Revenue Growth (YoY) | -7.10% |
| Gross Profit | $161.76M |
| Operating Income | -$49.58M |
| Pretax Income | -$56.13M |
| Net Income | -$55.79M |
| EBITDA | -$40.48M |
| EBIT | -$48.94M |
| Reported EPS (TTM) | -$0.79 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 34.38% of the $179.30M in total assets.
| Cash and Equivalents | $7.76M |
|---|---|
| Total Debt | $56.26M |
| Net Debt | $48.50M |
| Net Debt Per Share | $0.74 |
| Working Capital | $72.61M |
| Shareholder Equity | $61.65M |
| Book Value Per Share | $0.94 |
| Tangible Book Value | $42.42M |
| Tangible Book Per Share | $0.65 |
| Total Assets | $179.30M |
| Total Liabilities | $117.65M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.83M of capital spending, operating cash flow left -$18.57M of free cash flow.
| Operating Cash Flow | -$8.74M |
|---|---|
| Capital Expenditures | $9.83M |
| Free Cash Flow | -$18.57M |
| FCF Per Share | -$0.29 |
| Depreciation and Amortization | $8.45M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -24.38%, against a 5-year average of -24.32%.
| Gross Margin | 79.55% |
|---|---|
| Operating Margin | -24.38% |
| Pretax Margin | -27.61% |
| Net Margin | -27.44% |
| EBITDA Margin | -19.91% |
| EBIT Margin | -24.07% |
| FCF Margin | -9.13% |
| Gross Margin (5Y Average) | 81.10% |
| Operating Margin (5Y Average) | -24.32% |
| Net Margin (5Y Average) | -26.56% |
Growth
Revenue grew 14.46% a year over 3 years.
| Revenue Growth (3Y CAGR) | +14.46% |
|---|---|
| Revenue Growth (5Y CAGR) | +29.96% |
| Book Value Per Share Growth (2Y CAGR) | -21.79% |
| Tangible Book Per Share Growth (2Y CAGR) | -25.11% |
Dividends and Yields
TMCI does not pay a dividend. Its free cash flow yield is -6.39%.
| FCF Yield | -6.39% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 12 similar companies, TMCI has the 10th highest P/S.
P/S RatioPeer median 2.4x
ROICPeer median -6.60%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.21%
| P/S Ratio | 1.4x vs 2.4x median |
|---|---|
| ROIC | -32.79% vs -6.60% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -7.10% vs +14.21% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.84% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.84% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TMCI
What is TMCI's market cap?
Treace Medical Concepts has a market cap of $345.50M. Its enterprise value, which adds debt and subtracts cash, is $394.00M.
How many shares of TMCI are outstanding?
Treace Medical Concepts has 65.46M shares outstanding. The count is up 3.07% from a year earlier.
Does TMCI pay a dividend?
No. Treace Medical Concepts does not pay a dividend.
How much debt does TMCI have?
Treace Medical Concepts has $56.26M of total debt and $7.76M of cash and equivalents, a net debt position of $48.50M.
TMCI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts